Lenvatinib plus EGFR inhibition for liver cancer

Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):675. doi: 10.1038/s41575-021-00513-6.
No abstract available

Publication types

  • Comment

MeSH terms

  • ErbB Receptors
  • Humans
  • Liver Neoplasms* / drug therapy
  • Phenylurea Compounds / therapeutic use
  • Quinolines* / therapeutic use

Substances

  • Phenylurea Compounds
  • Quinolines
  • EGFR protein, human
  • ErbB Receptors
  • lenvatinib